Janssen Global Services Raritan

Raritan, United States

Janssen Global Services Raritan

Raritan, United States
SEARCH FILTERS
Time filter
Source Type

Robinson D.,Janssen Global Services Raritan | Orlowski R.Z.,University of Houston | Stokes M.,Evidera Montreal | He J.,Janssen Global Services Raritan | And 4 more authors.
European Journal of Haematology | Year: 2017

Objective: The direct cost of relapsed or refractory multiple myeloma (RRMM) is documented; indirect costs are being explored. Healthcare payers seek cost-offsets from therapies that improve clinical outcomes but challenge budgets; employers seek lower absenteeism and better productivity. Study goals were to: (i) identify direct and indirect economic factors of RRMM, and (ii) explore longitudinal relationships between clinical, economic, and health-related quality of life (HRQoL) assessments. Methods: Economic questionnaire, clinical, and HRQoL data from a multisite, international, randomized, controlled study in RRMM were analyzed. Results: Patients (n=263) were 53.6% male, 91.6% Caucasian; mean age of 62.9 years, median Eastern Cooperative Oncology Group status of 1 (56.3%). Moderate to severe pain or fatigue was reported by 30.4% and 70.6%, respectively. At baseline, ≥1 hospitalization was reported by 107 (41.8%); 182 (71.1%) and 86 (33.6%) reported specialist and family physician visits, respectively. A total of 28 (10.8%) were working: 10 (37.0%) of which reported RRMM-driven absenteeism ≥1 day. Of those who were not working, 110 (48.2%) indicated that it was due to RRMM. Multivariate modeling showed lower hospitalization with a major tumor response (β=-1.44, CI: -2.89 to 0.01, P=.05). Conclusions: Substantial RRMM indirect, social costs were observed. Better major tumor response may reduce hospital visits. © 2017 John Wiley & Sons A/S.

Loading Janssen Global Services Raritan collaborators
Loading Janssen Global Services Raritan collaborators